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Abstract
MicroRNAs are a class of small noncoding RNAs that function as critical gene regulators through targeting mRNAs for
translational repression or degradation. In this study, we showed that miR-128 expression levels were decreased in glioma,
and identified p70S6K1 as a novel direct target of miR-128. Overexpression of miR-128 suppressed p70S6K1 and its
downstream signaling molecules such as HIF-1 and VEGF expression, and attenuated cell proliferation, tumor growth and
angiogenesis. Forced expression of p70S6K1 can partly rescue the inhibitory effect of miR-128 in the cells. Taken together,
these findings will shed light to the role and mechanism of miR-128 in regulating glioma tumor angiogenesis via miR-128/
p70S6K1 axis, and miR-128 may serve as a potential therapeutic target in glioma in the future.
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Introduction
MicroRNAs (miRNAs) are a class of endogenously expressed
small noncoding RNAs that are usually 18,23 nucleotides long,
and regulate gene expression posttranscriptionally by targeting the
untranslated regions [1]. MiRNAs have been shown to participate
in a variety of cellular functions including cell apoptosis, cell
proliferation, neural development, and stem cell differentiation [1–
3]. They have been identified as a new kind of gene expression
regulators through targeting mRNAs for translational repression
or degradation [4]. Gliomas are the most common type of primary
brain tumors in adults. Among gliomas, astrocytomas have the
highest incidence [5]. According to World Health Organization’s
classification, astrocytomas are divided into four grades: pilocytic
astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, and
glioblastoma multiforme (GBM). Anaplastic astrocytoma and
glioblastoma multiforme are considered malignant glioma.
Recently, many miRNAs are found to play important roles in
glioma. MiR-7 was down-regulated in glioblastoma which
inhibited invasiveness of primary glioblastoma lines [6], while
miR-26 promotes glioblastoma cell proliferation in vitro and tumor
growth in vivo by targeting several tumor suppressor genes such as
PTEN and RB1 [7]. MiR-128 is a brain-enriched miRNA [8].
Most of the studies of miR-128 in carcinogenesis are focusing on
glioma. For example, miR-128 has been shown to be down-
regulated in glioma [8–10]. Overexpression of miR-128 inhibits
cell proliferation by targeting E2F3a and Bmi-1, and reduces
neuroblastoma cell motility and invasiveness through inhibiting
Reelin and DCX [8,10,11]. However, further investigation needs
to be performed to elucidate the role of miR-128 in carcinogenesis
and tumor development of glioma.
P70S6K1 is one of the key downstream targets of mammalian
target of rapamycin (mTOR), which plays important roles in
cancerous characteristics such as cell cycle, cell apoptosis, cell
growth and proliferation [12,13]. Growing evidence indicates that
p70S6K1 pathway is involved in carcinogenesis, metastasis and
chemotherapeutic drug resistance [12–14]. Our previous studies
have demonstrated that mTOR/p70S6K1 is involved in regulat-
ing tumor angiogenesis and tumorigenesis [15–17]. Tumor
angiogenesis is required for tumor development and growth.
Vascular endothelial growth factor (VEGF) is considered to be the
most important growth factor among the angiogenic factors
[18,19]. Hypoxia-inducible factor 1 (HIF-1) is one of the major
regulator of VEGF [20]. High levels of HIF-1 expression are
observed in many human cancers, and correlated with tumori-
genesis [21]. P70S6K1 is implicated in regulating HIF-1a
expression [15,16,22,23]. However, it is unclear what miRNAs
directly regulate p70S6K1 in glioma.
In the present study, we found that miR-128 was down-
regulated in human glioma and acted as a tumor suppressor by
directly targeting p70S6K1. Forced expression of miR-128
inhibited p70S6K1, HIF-1a, and VEGF expression. Overexpres-
sion of p70S6K1 restored miR-128-inhibited HIF-1a and VEGF
expression, confirming that p70S6K1 is the downstream target of
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proliferation and attenuated tumor growth and angiogenesis in
vivo. These results give novel insights into our understanding the
role and mechanism of miR-128 in glioma pathoetiology, and
provide a potential therapeutic strategy for glioma treatment in the
future.
Materials and Methods
Human tissue samples
All human normal brain and glioma tissue samples were
obtained from the Department of Neurosurgery, the first affiliated
hospital of Nanjing Medical University. This study procedure was
approved by The Institutional Review Board at the hospital. All
participants provided written informed consent. Tissue samples
were collected during surgery. For each sample, the major portion
of tissue was frozen immediately in liquid nitrogen for molecular
analysis, and the remaining tissue was fixed in paraformaldehyde
for histological examination. All samples were histologically
classified and graded according to WHO guidelines by clinical
pathologist, and were prepared for cases in the institute
biorepository, and classified and selected based on diagnosis. No
information regulated by The Health Insurance Portability and
Accountability Act was included in the study, which qualifies for
the status of USA NIH Exemption # 4.
Cell culture and reagents
Human glioma cell lines, U87 and U251 were cultured in
DMEM medium supplemented with 10% fetal bovine serum
(FBS), 100 units of penicillin/ml, and 100 ng of streptomycin/ml.
HEK-293 cells were cultured in DMEM medium supplemented
with 10% FBS, 100 units of penicillin/ml, 100 ng of streptomy-
cin/ml., and 2 mmol/ml glutamine. All cells were incubated at
37uC supplemented with 5% CO2. Antibodies against HIF-1a and
HIF-1b, and the growth factor-reduced Matrigel were from BD
Biosciences (Bedford, MA, USA). The antibodies against phospho-
p70S6K1 (Thr389), p70S6K1 were from Cell Signaling Technol-
ogy (Beverly, MA, USA). Monoclonal antibody against b-actin was
from Sigma. Antibodies against GAPDH were from Kangcheng
Company (Shanghai, China).
Lentiviruses packaging and stable cell lines
The hsa-miR-128 and hsa-miR-scrambled control (miR-SCR)
lentiviral constructs were purchased from Thermo Fisher Scientific
(Huntsville, AL, USA). To establish stable cells expressing miR-
128 and miR-SCR, lentiviruses were packaged using Lentiviral
Packaging System according to the manufacturer’s instructions
(Thermo Fisher Scientific). The lentiviral supernatant obtained
from HEK-293 cells was used to transduce U87 and U251 cells.
Stable cell lines were selected by puromycin.
RNA extraction, reverse transcription PCR and
quantitative real time- PCR
Total RNAs were extracted from cells with Trizol (Invitrogen,
CA, USA). One microgram of RNAs was used for cDNA synthesis
using oligo(dT)15 and M-MLV reverse transcriptase. Aliquots of
cDNAs were amplified with primers for VEGF and GAPDH. The
primers are as follows: VEGF forward primer, 59-TCGGGC-
CTCCGAAACCATGA-39; VEGF reverse primer, 59-CCTGG-
TGAGAGATCTGGTTC-39; GAPDH forward primer, 59-CC-
ACCCATGGCAAATTCCATGGCA-39; GAPDH reverse prim-
er, 59-TCTAGACGGCAGGTCAGGTCCACC-39. VEGF and
GAPDH were amplified by PCR for 30 cycles with each cycle at
95uC for 1 min, 59uC for 30 s, and 72uC for 1 min. The relative
VEGF mRNA levels were normalized to those of GAPDH mRNA
levels using Quality One analysis software (Bio-Rad, USA).
To analyze miR-128 expression levels, RNAs were extracted
from tissues. The stem-loop RT-PCR assay was used to quantify
the miRNAs expression levels as described previously [24,25]. The
RT-PCR primers were as following: miR-128 RT primer: 59-C-
TCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGA-
AAAGAGA-39. miR-128 PCR primers: sense: 59-ACACTCCA-
GCTGGGTCACAGTGAACCGGTC-39; anti-sense: 59- TGGT-
GTCGTGGAGTCG-39. U6 RT primer: 59-TGGTGTCGTG-
GAGTCG. U6 PCR primers: Sense: 59-CTCGCTTCGGCAG-
CACA; anti-sense: 59-AACGCTTCACGAATTTGCGT. PCR
products were separated on 2.0% agarose gels stained with
ethidium bromide, and visualized under UV light. RNA input was
normalized to the level of human U6 snRNAs. qRT-PCR was
performed using SYBR Premix DimerEraser (Takara, Dalian,
China) on a 7900HT system. MiR-128 and U6 PCR primers were
the same as described previously. The expression levels of miR-
128 were normalized with reference to expression levels of U6
snRNA, and fold changes were calculated by relative quantifica-
tion (2
2DDCt) [26].
Vector construction
pRK7-HA-S6K1 expression vector was as previously described
[27]. The p70S6K1 39-UTR sequence was amplified from human
cDNAs by PCR using the following primers: p70S6K1 forward
primer, 59-CGCGGATCCGTAAATGGCTTGTGATACTCT-
TGA-39; p70S6K1 reverse primer, 59-CGCCTCGAGATAG-
GTGTGTGCTTTCTGTCTGTG-39. For its mutagenesis, the
sequence complementary to the binding site of miR-128 in its
39UTR (CACTGTGA) was replaced by CAGTCTCA. The wild-
type and mutated 39-UTRs of p70S6K1 were cloned into pMIR-
REPORT miRNA reporter vector using the Sacl and HindIII
sites. These constructs were validated by sequencing.
Luciferase assay
HEK-293 cells were seeded into a 24-well plate. After cultured
overnight, cells were co-transfected with the wild-type and
mutated p70S6K1 39-UTR reporter plasmid, and pRL-TK
plasmids, or transfected with pre-miR-128 and miR-scrambled
control precursors (miR-SCR). Luciferase assays were performed
48 h after transfection using the Dual Luciferase Reporter Assay
System (Promega, WI, USA).
MiRNA precursor transfection
Pre-miR-128 and miR-SCR precursors were purchased from
Applied Biosystems (Carlsbad, CA). Cells at 50–70% confluence
were transfected using lipofectamine reagent (Invitrogen, CA,
USA). Transfection complexes were prepared according to the
manufacturer’s instructions. The final concentration of miR-128
or miR-SCR precursor for the transfection was 40 nmol/L.
Immunoblotting
After specific treatments as indicated, cells were washed with ice-
cold PBS buffer, scraped from the dishes, and centrifuged. The
supernatant was collected as the total cellular protein extracts and
stored at 280uC. Cell lysates were prepared using RIPA buffer
supplemented with protease inhibitors (100 mM Tris, pH 7.4,
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% deoxycholate
acid, 0.1% SDS, 2 mM phenylmethylsulfonyl fluoride, 1 mM
sodium orthovanadate, 2 mM DTT, 2 mM leupeptin, 2 mM
pepstatin). Tumor tissues from human and nude mice were grinded
into powder in liquid nitrogen with RIPA buffer, and the total tissue
MiR-128 Targets p70S6K1
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lysates were fractionated by SDS-PAGE, transferred to a nitrocel-
lulose membrane (Whatman, Germany), and subjected to immuno-
blotting analysis according to the manufacturer’s instruction. ECL
Detection System (Thermo Scientific) was used for signal detection.
ELISA assay for VEGF
The protein levels of VEGF in the supernatant were measured
using the Quantikine human VEGF ELISA kit (NeoBioscience,
Shanghai, China) according to the manufacturer’s instruction. In
brief, the cells were seeded in 6-well plates and cultured to 90%
confluence, and then cells were switched to fresh medium. The
supernatants were collected and the number of cells in each well
was counted after 24 h. VEGF in the supernatant (100 ml) was
determined, and normalized to the cell number. A serial dilution
of human recombinant VEGF was included in each assay to
obtain a standard curve.
Cell proliferation assay
To determine the effects of miR-128 on the cell proliferation,
U87 and U251 cells (6610
4 cells) were seeded in a 6-well plate and
cultured overnight. The cells were transiently transfected with pre-
miR-128 and miR-SCR precursors, respectively; and cultured
overnight. Then the cells were trypsinized and seeded at 2000 cells
per well in a 96-well plate. The proliferation of the cells was
measured using a Cell Counting Kit-8 (CCK-8) (Dojindo
Laboratories, Kumamoto, Japan) according to the manufacturer’s
instruction every 24 h after transfection. Three independent
experiments were done in triplicate.
Tumorigenesis in nude mice
Male BALB/cA-nu nude mice (4-weeks-old) were purchased
from Shanghai Experimental Animal Center (Chinese Academy of
Sciences, Shanghai, China), and maintained in pathogen-free
conditions. Eight mice were randomly divided into two groups.
U87 cells stably expressing miR-128 were injected subcutaneously
into both flanks of nude mice (5610
6 cells in 100 ml). U87 cells
stably expressing miR-SCR were used as the negative control. Bi-
dimensional tumor measurements were measured with calipers
three times weekly. Tumor volumes were calculated according to
the formula (width
26length)/2. The mice were euthanized after
28 days, and tumors were weighed.
Matrigel plug assay
MaleBALB/cA-nunude mice(6-weeks-old) were purchasedfrom
Shanghai Experimental Animal Center (Chinese Academy of
Sciences, Shanghai, China), and maintained in pathogen-free
conditions. Eight mice were randomly divided into two groups.
U87 cells stably expressing miR-128 were harvested and resus-
pended in serum-free medium. Aliquots of the cells (2610
6 cells in
100 ml) were mixed with 200 ml of Matrigel. The mixture was
immediately injected into both flanks of nude mice. U87 cells stably
expressing miR-SCR in equal volumes of solvent were used as the
control. On Day 11 after the implantation, the Matrigel plugs were
trimmed out and used for the measurement of the hemoglobin
content using Drabkin’s Reagent Kit (Sigma-Aldrich, St Louis, MO)
according to the manufacturer’s instructions. The concentrations of
hemoglobin were calculated based on a set of hemoglobin standards.
Immunohistochemical analysis
Tumors samples were fixed in Bouin’s solution and embedded in
paraffin. Tumor sections at 5 mm were cut and deparaffinized, and
antigen was retrieved by the heating using microwave for 15 min.
After incubation with hydrogen peroxide, the sections were washed
with16PBSbufferforthree times.Thesectionswereblockedfor1 h
with 5% Albumin Bovine serum in PBS buffer. Antibodies against
HIF-1a (Bioworld, China), VEGF(Santa Cruz, CA, USA) and anti-
Human CD31 (Abcam,USA) were used ina humidchamber at 4uC
for 16 h. After washing three times, the sections were incubated with
EnVision+, Peroxidase, Rabbit (Gene Tech, Shanghai, China) for
2 h. The protein signals were detected using 3,39-diaminobenzidi-
ne(DAB) (Gene Tech, Shanghai, China). Different sections were
prepared from three of the Matrigel plugs in every group, and the
microvessels were counted in three different fields per section as
follows: slides were first scanned under low power (6100) to
determine three ‘‘hotspots’’ or areas with the maximum number of
microvessels, then the positive-stained blood vessels in the selected
areas were analyzed at 6400 magnification [17].
Statistical analysis
All values in this study were presented as mean+SD. Statistical
analysis was performed based on a Student’s t-test at the
significance level of P,0.05. Spearman’s correlation analysis was
used to determine the correlation of the expression levels of
p70S6K1, miR-128, and the CD31-positive microvessel densities
using SPSS software.
Results
MiR-128 expression was decreased in gliomas
To determine the levels of miR-128 in glioma and normal brain
tissues, total RNAs were extracted from normal brain tissues and
glioma tissues at Grades II, III, and IV, and the expression levels
of miR-128 were analyzed using RT-PCR and real time PCR. As
shown in Figure 1A, the expression levels of miR-128 were down-
regulated in glioma tissues when compared to the normal brain
tissues. The levels of miR-128 expression were quantified using
Figure 1. MiR-128 was down-regulated in human glioma
tissues when compared to normal brain tissues. (A) Semi-
quantative RT-PCR analysis of miR-128 levels in three normal brain
tissues (N1–N3) and twelve glioma tissues (T1–T4 Grade II, T5–T8 Grade
III, T9–T12 Grade IV). U6 RNA level was used as an internal control. (B)
Relative miR-128 expression levels were analyzed by qRT-PCR in normal
brain tissues and three grades of glioma tissues (Grade II, Grade III,
Grade IV). U6 RNA level was used as an internal control. Double asterisks
indicate significant difference when compared to normal brain tissues
(P,0.01).
doi:10.1371/journal.pone.0032709.g001
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with thirteen cases each, and normalized to the U6 levels. The
levels of miR-128 expression in glioma tissues were significantly
decreased when compared with normal tissues (Figure 1B). There
was no significant difference of miR-128 expression levels in
glioma tissues between Grade III and Grade IV, which was
significantly lower than that in Grade II (Figure 1B). This result
indicates that miR-128 is down-regulated in glioma.
P70S6K1 was a direct target of miR-128
To better understand molecular action of miR-128 in glioma,
we searched for potential targets of miR-128 by TargetScan, and
tested the potential targets using bioinformatic database. We found
that miR-128 has a putative binding site to the 39-UTR region of
p70S6K1 with 100% conserved sequence in human, mouse, and
rabbit (Figure 2A). The p70S6K1 39-UTR was cloned into pMIR-
REPORT miRNA reporter vector. Overexpression of miR-128
decreased luciferase activity of this reporter to 70% of the control
level (Figure 2B), suggesting that miR-128 inhibits the 39-UTR
function of p70S6K1. To test whether miR-128 specifically
inhibited p70S6K1 by its potential binding site of seed sequence,
the mutated reporter at miR-128 binding site was constructed.
Forced expression of miR-128 did not affect the mutant p70S6K1
reporter activities (Figure 2B). These results indicate that p70S6K1
Figure 2. MiR-128 directly targeted p70S6K1. (A) Schematic diagram of putative miR-128 binding site in the 39-UTR regions of p70S6K1 in
human, mouse and rabbit. The seed sequence of miR-128 matches 39-UTR regions of p70S6K1 (in bold). The mutated nucleotides of the p70S6K1 39-
UTR was labeled by asterisk. (B) Relative luciferase activities of p70S6K1 wild type (WT) and mutant (Mut) 39-prime UTR regions were obtained by co-
transfection of scrambled control miRNA or miR-128 precursor, and pRL-TK plasmid; and calculated as the ratio of firefly/renilla activities in the cells
and normalized to those of the control. The results were presented as mean6SD from three independent experiments with each experiment in
triplicate. Asterisk indicates significant difference when compared to control (P,0.05). (C) U87 and U251 cells stably expressing scrambled control
(SCR) and miR-128 were subjected to RT-PCR analysis for miR-128 and U6 expression levels. (D) Overexpression of miR-128 inhibited p70S6K1
expression at protein level. The expression levels of total p70S6K1, phospho-p70S6K1 (Ser389), and GAPDH protein in U87 and U251 cells stably
expressing miR-SCR and miR-128 were analyzed by immunoblotting. (E) Relative signals were quantified using VisionworksLS Acquisition and analysis
software. Results are presented as mean6SD from three independent experiments. Double asterisks indicate significant difference when compared
to the control (P,0.01). (F) miR-128 overexpression did not change the p70S6K1 mRNA level detected by RT-PCR. Relative densities were quantified
using VisionworksLS Acquisition and analysis software.
doi:10.1371/journal.pone.0032709.g002
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seed sequence.
Next, we established cell lines stably expressing miR-128 and its
scrambled control (miR-SCR) using human glioma cells U87 and
U251 by lentiviral transduction. The expression levels of miR-128
were analyzed in these stable cell lines using RT-PCR. As shown
in Figure 2C, the expression levels of miR-128 were increased in
pLe-miR-128-expressing U87 and U251 cells, respectively,
demonstrating that these stable cells successfully expressed miR-
128. The cells with miR-128 overexpression showed low levels of
p70S6K1 and p-p70S6K1 proteins by 30–50% reduction when
compared to those of scrambled control cells (Figures 2D and 2E).
In addition, forced expression of miR-128 did not change
p70S6K1 mRNA expression levels (Figure 2F), showing that
miR-128 specifically regulates p70S6K1 protein expression at
posttranscriptional levels.
P70S6K1 levels inversely related to the levels of miR-128
expression in glioma tissues
To determine whether the reduced miR-128 expression
correlates with the levels of p70S6K1 expression in tumor tissues,
protein expression of p70S6K1 in glioma and normal brain tissues
was analyzed by immunoblotting. The results revealed that the
protein levels of p70S6K1 in glioma tissues were dramatically
higher than those in normal brain tissues (Figure 3A). As shown in
Figure 3B, Spearman’s correlation test showed a significant inverse
Figure 3. The p70S6K1 protein levels were negatively correlated with miR-128 levels in glioma tissues. (A) The expressions of p70S6K1
in human glioma specimens and normal brain tissues were determined by immunoblotting and the fold changes were obtained by the ratio of
p70S6K1 to GAPDH level. Double asterisks indicate significant difference when compared to normal brain tissues (P,0.01). (B) Spearman’s correlation
analysis was used to determine the correlation between the expression levels of p70S6K1 and miR-128 by SPSS software (Spearman’s correlation
analysis, r=20.741; P,0.001).
doi:10.1371/journal.pone.0032709.g003
Figure 4. Overexpression of miR-128 inhibited HIF-1 and VEGF expression. Stable U87 and U251 cell lines expressing scrambled miRNA
(SCR) or miR-128 were established. (A) Levels of HIF-1a, HIF-1b, and GAPDH protein expression were detected by immunoblotting (B) VEGF mRNA
levels were detected by semi-quantitative RT-PCR assay. Asterisk and double asterisks indicate significant difference when compared to U87 cell
expressing miR-SCR or U25 cell expressing miR-SCR at P,0.05 or at P,0.01, respectively. (C) VEGF protein levels were detected by ELISA assay.
Double asterisks indicate significant difference when compared to the control (P,0.01).
doi:10.1371/journal.pone.0032709.g004
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glioma tissues with Spearman’s correlation, r=20.741 (P,0.001),
confirming that lower expression levels of miR-128 were
significantly associated with higher levels of p70S6K1 protein
expression in the same set of glioma tissues.
Overexpression of miR-128 inhibited HIF-1a and VEGF
expression
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric tran-
scription factor composed of HIF-1a and HIF-1b subunits [28].
HIF-1b protein is constitutively expressed in most human cells. In
contrast, HIF-1a expression is induced in the cells by hypoxia,
growth factors, and oncogenes [29,30]. High levels of HIF-1a
expression are observed in many human cancers, and correlated
with tumor growth. Previous results showed that p70S6K1 was the
upstream regulator of HIF-1a expression [15,17,22]. To deter-
mine whether suppression of p70S6K1 expression due to miR-128
overexpression affects HIF-1 expression in glioma, we found that
HIF-1a but not HIF-1b protein levels were inhibited in U87 and
U251 cells stably expressing miR-128 when compared to cells
stably expressing miR-SCR (Figure 4A). VEGF, the critical
regulator of angiogenesis, is mainly regulated by HIF-1a through
the binding to the hypoxia-responsive element of VEGF promoter
region. In consistent with decreased HIF-1a levels, the VEGF
levels in miR-128-expressing U87 and U251 cells were down-
regulated to 55% and 30%, respectively (Figure 4B). Moreover,
VEGF protein levels in the medium were tested by ELISA as
previously described [15], and the results showed that overex-
pression of miR-128 inhibited VEGF protein production
(Figure 4C). These results suggest that forced expression of miR-
128 inhibited HIF-1a and VEGF expression via p70S6K1
signaling.
Figure 5. Overexpression of p70S6K1 restored the inhibitory effects of miR-128 in HIF-1 and VEGF expression. U87 and U251 cells
stably expressing miR-SCR or miR-128 were transfected with p70S6K1 cDNA plasmid without 39 UTR at 2 mg per well. After transfection for 48 h, the
levels of specific proteins were analyzed by immunoblotting. (A) Overexpression of p70S6K1 increased levels of p70S6K1, phospho-p70S6K1, HIF-1a
and HIF-1b protein expression. (B) Forced expression of p70S6K1 restored VEGF mRNA expression inhibited by miR-128. The levels of VEGF and
GAPDH were analyzed by semi-quantitative RT-PCR and normalized to the control level. Double asterisks indicate significant difference of VEGF levels
between the control and miR-128 treatment (P,0.01). Double hashes indicate significant difference of VEGF in the cells with versus without p70S6K1
overexpression (P,0.01).
doi:10.1371/journal.pone.0032709.g005
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effects of miR-128
As we showed above, p70S6K1 is a direct target of miR-128.
Therefore, we wondered whether forced expression of p70S6K1 is
enough to reverse the expression of miR-128-inhibited down-
stream molecules. P70S6K1 cDNA plasmid without 39UTR
region was transfected into miR-128- or miR-SCR-expressing
cells. As shown in Figure 5A, the decreased level of p70S6K1 by
miR-128 expression was rescued via the introduction of p70S6K1
cDNA. Similarly, ectopic expression of p70S6K1 also restored
miR-128-inhibited HIF-1a and VEGF expression in both U87
and U251 cells (Figures 5A and 5B), indicating that miR-128
inhibits HIF-1a and VEGF expression by targeting p70S6K1.
MiR-128 attenuated cell proliferation and tumor growth,
and decreased p70S6K1 protein level in tumor xenografts
P70S6K1 signaling pathway plays an important role in
regulating cell cycle and cell proliferation [31,32]. To study
whether miR-128 can regulate cell growth by targeting p70S6K1,
cell proliferation was analyzed by Cell Counting Kit-8 (CCK-8)
assay. When compared to miR-SCR treatment, overexpression of
miR-128 in U87 and U251 cells inhibited cell proliferation after
the culture for 3–4 days, suggesting that miR-128 affects cell
growth in vitro (Figure 6A). To further clarify the inhibitory effect of
miR-128 on tumor growth in vivo, U87 cells stably expressing miR-
128 were injected subcutaneously into both flanks of the nude
mice. Cells stably expressing miR-SCR were used as negative
control. The lengths and widths of tumors were measured when
the xenografts were visible on Day 18, and the volumes of tumors
were calculated. As shown in Figure 6B, the size of xenografts from
miR-128-expressing cells was smaller than that from miR-SCR
control group after 20 days of implantation. After 28 days, the
xenografts were trimmed out, and tumor weight was measured.
Forced expression of miR-128 in U87 cells attenuated tumor
growth by 75% when compared to miR-SCR control group
(Figures 6C and 6D). Furthermore, the protein levels of p70S6K1
in xenografts from miR-128-expressing cells were much lower
Figure 6. Overexpression of miR-128 inhibited cell proliferation and tumor growth. (A) U87 and U251 cells were transiently transfected
with miR-SCR or pre-miR-128 precursor. After the transfection for 24 h, cells were trypsinzed and seed into 96-well plate (2000 cells/well). Cell
proliferation was determined after 24, 48, 72, and 96 h by using Cell Counting Kit-8 (CCK-8) to detect the absorbance at 450 nm. Values represent
means 6 standard deviation (SD). Double asterisks indicate significant difference when compared to the miR-SCR group (P,0.01). (B) Nude mice
were injected subcutaneously with 5610
6 U87 cells stably expressing miR-128 (miR-128) or miR-SCR. Each treatment group contained 8 tumors.
When the xenografts were visible, the width and length of tumors were measured. Asterisk indicates significant difference when compared to the
miR-SCR group (P,0.05). (C) The mice were euthanized on Day 28 and the xenografts were trimmed out. Representative tumors from each group
were shown. Scale bar, 2 mm. (D) Overexpression of miR-128 significantly inhibited tumor growth in vivo. The tumor weight was measured for each
xenograft. After 28 days, the weight of tumors from miR-128 group decreased by 75% compared to SCR group. Double asterisks indicate significant
difference when compared to the miR-SCR group (P,0.01). (E) The levels of p70S6K1 from the tumor tissues of miR-128-expressing group were much
higher than that of SCR control group by immunoblotting assay. (F) The expression levels of HIF-1a and VEGF were analyzed in tumor tissues by
immunohistochemistry with representative images showed. Magnification, 6200.
doi:10.1371/journal.pone.0032709.g006
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miR-128 overexpression suppressed p70S6K1 expression in vivo.
The expression levels of HIF-1a and VEGF in the tumor sections
were also higher in miR-SCR control group than those in miR-
128-expressing group (Figure 6F). These results indicate that miR-
128 inhibits cell proliferation and tumor growth.
MiR-128 inhibited angiogenesis in nude mice
In previous studies, we demonstrated that miR-128 down-
regulated HIF-1a and VEGF expression by targeting p70S6K1.
HIF-1a expression is frequently increased in many human cancers
and is associated with angiogenesis induced by tumors and
hypoxia [21]. Our group and others have demonstrated that
p70S6K1 signaling is required for HIF-1-mediated VEGF
expression in response to growth factor stimulation and oncogene
activation [15–17]. To test whether miR-128 inhibits tumor
angiogenesis, U87 cells stably expressing miR-128 or miR-SCR
were mixed with Matrigel and injected into both flanks of the nude
mice. The mice were sacrificed 11 days after implantation. The
Matrigel plugs from the mice implanted with miR-128-expressing
cells were represented in Figure 7A. The relative angiogenesis
responses were assayed by measuring the hemoglobin levels. When
compared to miR-SCR group, the angiogenesis responses in miR-
128 group were decreased by 50% (Figure 6B). In addition, the
number of CD31-positive microvessels was much lower in the
sections from xenografts of miR-128-expressing U87 cells
Figure 7. Overexpression of miR-128 suppressed tumor angiogenesis in vivo. U87 cells stably expressing miR-128 or miR-SCR were
trypsinized and resuspended in serum-free medium at 2610
6cells/ml, and aliquots of the cells (0.1 ml) were mixed with 0.2 ml of growth-factor-
reduced Matrigel, and injected subcutaneously into the nude mice. The mice were euthanized after the implantation for 11 days. (A) The
representative Matrigel plugs are shown. Scale bar, 2 mm. (B) The hemoglobin levels in 8 tumors from miR-128 group decreased to 50% compared to
SCR control group. Asterisk indicates significant difference when compared to the miR-SCR group (P,0.05). (C) Representative tumor sections stained
by antibody against human CD31. Magnification, 6200. (D) CD31-positive microvessels were counted from 8 tumors in three different fields per
section at 6400 magnification. Asterisk indicates significant difference when compared to the miR-SCR group (P,0.05). (E) Representative normal
and different grades of glioma tumor sections stained by antibody against human CD31. Magnification, 6200. (F) Spearman’s correlation test was
used to analyze the correlation of miR-128 levels and CD31-positive microvessel densities from 15 glioma tumors using SPSS software.
doi:10.1371/journal.pone.0032709.g007
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cell-inducing angiogenesis. Furthermore, we selected four cases in
every grade of glioma tissues, and analyzed the number of CD31-
positive microvessels in glioma specimens, the normal brain tissues
were used as negative control. As shown in Figure 7E, the number
of CD31-positive microvessels was much lower in normal brain
tissue sections than those in glioma specimens. We analyzed
CD31-positive microvessel density and miR-128 expression levels
in the glioma tissues using SPSS software, and found that there is a
significant inverse correlation of miR-128 levels and the CD31-
positive microvessel densities in glioma tissues with Spearman’s
correlation, r=20.673 (P,0.05).
Discussion
MiRNAs function as post-transcriptional gene regulators in
regulating various physiological and pathological events [33].
MiRNA abnormalities are thought to play important roles in
cancer development. Recent studies have showed that many
miRNAs are down-regulated in tumors when compared to normal
tissues [34]. Consistent with previous studies [9,10], we demon-
strated that the expression of miR-128 in glioma tissues was down-
regulated when compared to normal brain tissues. The results
indicate that miR-128 is involved in pathogenesis of glioma. To
determine the role and molecular mechanism of miR-128 in
glioma development, we used computational bioinformatics to
predict the potential targets of miR-128. Among the potential
targets, we confirmed that p70S6K1 is a novel target of miR-128
by experimental method with forced expression of miR-128
suppressing p70S6K1 protein expression. In agreement with these
results, overexpression of p70S6K1 rescued the inhibitory effect of
miR-128 on p70S6K1 signaling pathway. Interestingly, the levels
of miR-128 were negatively correlated with p70S6K1 protein
levels in glioma tissues. Thus, this study is useful not only to reveal
a novel mechanism of miR-128 in regulating glioma growth
through targeting p70S6K1, but also to potentially use the
alterations of miR-128/p70S6K1 axis for the diagnostics and
treatment of glioma in the future.
Angiogenesis is the process by which new microvessels sprout
from the pre-existing blood vessels. The pathophysiological
processes of angiogenesis and tumor cell invasion play pivotal
roles in glioma development and growth in the earliest phase and
closely related to drug resistance against chemotherapy [35,36].
Angiogenesis is required for tumor growth and metastasis. Our
previous studies have showed that p70S6K1 played an important
role in regulating HIF-1a and VEGF expression [15,22]. Here we
found that miR-128 overexpression can inhibit HIF-1a and VEGF
expression through targeting p70S6K1. Consistent with these in
vitro experiments, forced expression of miR-128 attenuated tumor
growth and angiogenesis in nude mice. Furthermore, our results
showed that miR-128 expression levels were inversely correlated
with the CD31-positive microvessel densities in glioma tumor
tissues. These findings indicated a new role and mechanism of
miR-128 in angiogenesis and tumor growth.
In summary, we identified that miR-128 inhibited tumorigen-
esis and angiogenesis through targeting p70S6K1 and suppressing
p70S6K1downstream molecules such as HIF-1 and VEGF. This
study identified a link between miR-128 and p70S6K1 axis, which
plays vital role in glioma angiogenesis, and provided a potential
new target in glioma diagnostics and therapy in the future.
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